Introduction {#Sec1}
============

Coronary heart disease (CHD) remains a leading cause of death in developed countries^[@CR1]^. Numerous risk factors for the incidence of CHD and acute coronary syndrome (ACS) have been well-validated, including hyperlipidemia, arterial hypertension, diabetes, smoking and family history of CHD^[@CR2]^. Biomarkers for the prognosis post-ACS have been suggested, such as Growth Differentiation Factor-15 (GDF-15) or N-terminal pro-hormone brain natriuretic peptide (NT-proBNP)^[@CR3]^, but currently no biomarkers stratifying for risk of re-infarction have been identified.

Recently, a group of antibodies against various G protein coupled receptors including Beta1 adrenergic receptors (ß~1~AR) were identified in healthy individuals, which is altered by age, sex and certain diseases. These antibodies exhibit effects on the receptor as novel ligands and are important for immune cell homeostasis. Both increased as well as decreased ab concentrations were associated with diseases and disease symptoms^[@CR4]^.

Beta~1~AR is known to be expressed on endothelial cells, cardiomyocytes and fibroblasts. Existing data suggests that cardiac function may be influenced by regulating ß~1~AR^[@CR5],[@CR6]^. ß~1~AR affects both myocardial contractility^[@CR7]^ and heart rate regulation^[@CR8]^. Current literature suggests that autoantibodies against ß~1~AR (ß~1~AR Ab) may influence the development of cardiomyopathy^[@CR9]^, and in particular some evidence of prognostic benefit exists for ß~1~AR Ab in ischemic cardiomyopathy^[@CR10]^.

The immunological mechanisms of ß~1~AR Ab however remain unclear, with conflicting reports of both protective or negative effects on ß~1~AR as well as agonistic and antagonistic functions of ß~1~AR^[@CR10]--[@CR12]^. It would appear that the function of antibodies against ß~1~AR may depend~~s~~ upon the exact binding site and clinical status at the time of measurement, as for example different effects of ß~1~AR Ab were described in healthy individuals compared to patients with cardiomyopathy^[@CR13]^.

We previously demonstrated that significantly reduced anti ß~1~AR Ab concentrations were evident in patients with STEMI compared to other forms of ACS and healthy controls in a combined cohort of 212 ACS patients^[@CR14]^.

To validate these findings, a large scale assessment utilising the PLATO cohort was performed, paying particular attention to the role of ß~1~AR Ab regarding the incidence of re-infarction and cardiovascular death in the first year post index ACS event. Given recent evidence that age may influence autoantibodies against G protein coupled receptors regarding antibody levels and function has been shown recently^[@CR4]^. Earlier studies with autoantibodies in atherosclerosis and cardiovascular disease have been performed in younger CHD patients, below the age of 60 years, as differences regarding to the patients age in their quantity for example in MAZ-ab have been present^[@CR14]--[@CR16]^. For these reasons we were interested as well, if ß1AR Ab may have a different meaning in younger patients.

Methods {#Sec2}
=======

Serum samples from the Platelet Inhibition and Patient Outcomes (PLATO) trial, involving over 18.000 patients with ACS, were analyzed. Inclusion criteria consisted of hospitalization with ischemic symptoms within the previous 24 hours for ≥10 minutes, ≥18 years of age and not being pregnant. Minimum of two of the following criteria were mandatory:i.Compatible ECG changes (ST segment depression, transient ST-elevation ≥1 mm in two or more contiguous leads or new left bundle branch block)ii.Raised biomarkers (Troponin I/T or CK/MB)iii.Coronary angiography PCI planned.and one of the following:i.Age ≥60 yearsii.Previous MI or coronary by-pass, or known ischemic heart disease with ≥50% stenosis in ≥2 vesselsiii.Previous ischemic stroke, physician-confirmed transient ischemic attack, carotid stenosis (≥50%) or revascularizationiv.Diabetes mellitusv.Peripheral vascular diseasevi.Chronic renal dysfunction.

Comprehensive details are included in the original publication of the PLATO trial^[@CR17]^.

For the current analysis, STEMI and NSTEMI patients were selected chronologically, based on earliest recruitment to maximize follow-up data completeness. Anti-ß~1~AR Ab concentrations were measured in sera from all patients and compared to the primary outcome according to the same diagnostic criteria within the first year, with patient 1-year survival - both all-cause and cardiovascular-related - being the secondary outcome measures. Further sub-analysis, correlating individual antibody concentrations to documented cardiac risk factors, as well as sub-group stratification for patient age and ACS phenotype were additionally performed.

The current study was approved by the institutional ethics committees of the Medical School Hannover as well as the national and institutional regulatory authorities and ethics committees in Uppsala, Sweden. The methods were carried out in accordance with good clinical practice guidelines. All patients provided written informed consent before entering the PLATO trial.

Detection of anti-β~1~AR Ab using ELISA {#Sec3}
---------------------------------------

The commercially available CE-certified ELISA kit (CellTrend GmbH, Luckenwalde, Germany) for quantifying anti-β~1~AR Ab was used. ELISA Validation was performed according to the FDA's "Guidance for industry: Bioanalytical method validation"^[@CR18]^. Using native membrane extracts from cell lines overexpressing human β~1~AR to measure IgG antibodies against the transmembrane β~1~AR in its assumed physiological conformation^[@CR19],[@CR20]^. Tests were performed with microtiter polystyrene plates with 96 wells, which were coated with human ß~1~AR overexpressing extracts from transfected Chinese Hamster Ovary cells. To maintain the conformational epitopes of the receptor we added 1 mM calcium chloride to each buffer and incubated duplicate samples of a 1:100 dilution at 48 °C for 2 hours. After washing, an incubation followed for 1 hour with a 1:20.000 dilution of horseradish peroxidase-labelled goat anti-human IgG (Jackson, Bar Harbor, ME, USA) for detection. Plates were incubated with a human monoclonal antibody against ß~1~AR (anti-ß~1~AR mab), to be able to obtain a standard curve (Fig. [SD3](#MOESM1){ref-type="media"}). We generated a standard curve by standardizing antibody concentrations. For example (a) 6250 ng/ml anti-ß~1~AR mab for standard point 1, (b) 3125 ng/ml anti-ß~1~AR mab for standard point 2, (c) 1563 ng/ml anti-ß~1~AR mab for standard point 3, (d) 781 ng/ml anti-ß~1~AR mab for standard point 4 (e) 391 ng/ml anti-ß~1~AR mab for standard point 5 and (f) 195 ng/ml anti-ß~1~AR mab for standard point 6. Finally, the optical density was measured. All standard points were performed in duplicates. The threshold for anti-ß~1~AR mab detection was set at 100 ng/ml. Analysis of all patient probes, sera and plasma samples, was performed according to the described protocol by individuals who had no information regarding the patients' characteristics.

Statistical analyses {#Sec4}
--------------------

We used R version 3.3.2 (<http://www.r-project.org>) for all data analyses.

The concentrations of anti-β~1~AR Ab have been analyzed in groups separated by age (≤60/\>60 years) and ACS entity. Continuous variables were tested using either the Kruskal-Wallis rank sum test (\>2 groups) or the Wilcoxon rank sum test (2 groups). Categorical variables were evaluated using Fisher's exact test. Kaplan-Meier survival curves were constructed with patients being stratified according to anti-ß~1~AR Ab concentrations ≤ median and \>median, ACS phenotype (STEMI vs. NSTEMI) and (≤60 vs. \>60 years). Patient outcomes and anti-ß~1~AR Ab were analyzed within Cox proportional hazards models, fitted to the different outcomes using either anti-ß~1~AR Ab and STEMI/NSTEMI anti-ß~1~AR Ab and age group (≤60/\>60 years) and the respective interactions between them as variables.

To assess the relationship between anti-ß~1~AR Ab and conventional cardiovascular biomarkers the time of initial ACS presentation, scatterplots were constructed and given the continuous nature of both variables, Spearman rank correlations were performed.

Results {#Sec5}
=======

Cohort study {#Sec6}
------------

### Patients demographics {#Sec7}

Anti-ß~1~AR Ab concentrations were measured in sera of 399 NSTEMI and 400 STEMI patients enrolled in the PLATO ACS cohort. Patients were then stratified according to anti-ß~1~AR Ab concentration being either *greater than* or *less than or equal* to the median concentration. Sub-group baseline characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Whilst the majority of patients in both groups were male, no significance difference in gender (69.5% vs. 69.6%; p = 0.939) or age (median 61 \[52.8--70.0\] vs. 61 \[53.5--70.0\] years; p = 0.961) was evident between groups.Table 1Baseline characteristics of all patients included in the cohort analysis, grouped according to individual ß1-AR antibody titer compared to overall median titer value.DemographicsNß~1~AR Antibody Titer (ng/ml)p≤Median Titer\>Median TiterN400399Age, Years79961\[52.8--70\]61\[53.5--70\]0.961^a^Female, N (%)799122(30.5)120(30.1)0.939^b^Weight, kg79980\[70--90\]80\[71--90\]0.466^a^Body Mass Index, kgm^−2^79927.7\[25.0--30.8\]27.9\[25.3--31\]0.402^a^**Risk Factors**Habitual smoker, N (%)799152(38.0)164(41.1)0.386^b^Hypertension, N (%)799250(62.5)251(62.9)0.942^b^Dyslipidemia, N (%)799182(45.5)156(39.1)0.073^b^Diabetes mellitus, N (%)79995(23.8)72(18.0)0.055^b^**Clinical FactorsBlood Pressure**- *Systolic*, mmHg799138*\[120--150\]*140*\[120--153\]0.469* ^a^- *Diastolic*, mmHg79980*\[70--90\]*80*\[72--90\]0.113* ^a^Heart Rate, min^−1^79973\[64--82\]74\[66--86\]0.039^a^**Past Medical History**Angina Pectoris, N (%)799178(44.5)169(42.4)0.568^b^Myocardial Infarction, N (%)79962(15.5)66(16.5)0.701^b^Heart Failure, N (%)7998(2.0)21(5.3)0.014^b^Percutaneous Coronary Intervention, N (%)79942(10.5)38(9.5)0.724^b^Coronary Artery Bypass Graft, N (%)79917(4.2)11(2.8)0.336^b^Transient Ischemic Attack, N (%)7997(1.8)7(1.8)1.000^b^Ischemic Stroke, N (%)79913(3.2)10(2.5)0.673^b^Peripheral Arterial Disease, N (%)79930(7.5)21(5.3)0.247^b^Chronic Renal Disease, N (%)79912(3.0)14(3.5)0.696^b^Beta-blocker, N (%)799311(77.0)301(75.4)0.453^b^ACE inhibitor, N (%)799257(64.2)260(65.2)0.824^b^Statin, N (%)799339(84.8)363(91.0)0.009^b^Aspirin, N (%)799388(97.0)390(97.7)0.659^b^Clopidogrel, N (%)799120(30.0)96(24.1)0.067^b^**Acute Coronary Syndrome Phenotype**ST-Elevation MI, N (%)799159(39.8)241(60.4)0.001^b^**Serum Biomarkers**Apolipoprotein A1, g/L7471.0\[0.9--1.2\]1.0\[0.8--1.1\]0.412^a^Apolipoprotein B, g/L7470.8\[0.7--1.0\]0.8\[0.6--1.0\]0.740^a^C-Reactive Protein, mg/L7472.7\[1.2--6.2\]3.5\[1.4--8.4\]0.018^a^Cystatin, mg/L7470.7\[0.6--0.9\]0.8\[0.6--0.9\]0.315^a^Interleukin-6 pg/ml7903.1\[1.8--6.5\]3.5\[2.0--7.1\]0.146^a^NT-proBNP, pmol/L799391\[125--946\]336\[101--1007\]0.407^a^GDF-15 ng/l7991485\[1126--2011\]1609\[1161--2210\]0.055^a^GFR ml/min747120\[94--120\]120\[90--120\]0.237^a^Troponin-I, μg/L7471.1\[0.2--3.8\]0.8\[0.2--4.1\]0.534^a^Troponin-T, ng/L799173\[58--510\]194\[50--522\]0.938^a^Higher titers were more prevalent among ST-elevation myocardial infarction patients, as well as those with known heart failure. An association with moderate C-reactive protein elevation was observed. No association with traditional cardiovascular risk factors were evident. Values are Median \[Interquartile Range\] unless otherwise stated. ACE: angiotensin converting enzyme. BNP: brain naturetic peptide. GDF-15: Growth Differentiation Factor-15. GFR: glomerular filtration rate. ^a^Wilcoxon test; ^b^Fisher's exact test.

With regards to past medical history, a significantly higher incidence of heart failure was identified in patients with higher anti-ß~1~AR Ab concentrations was observed (2% vs. 5.3%; p = 0.014). Other than statin treatment (84.8% vs. 91.0%; p = 0.009), no significant differences in standard prophylactic treatments across all drug classes were identified within the cohort.

### Anti-ß~1~AR Ab, ACS phenotype and rate of re-infarction {#Sec8}

Comparing anti-ß~1~AR Ab levels between ACS phenotypes, a significantly higher proportion of STEMI patients exhibited concentrations of anti-ß~1~AR Ab above the median value (60.4% *vs*. 39.8%; p \< 0.001). Those exhibiting lower anti-ß~1~AR Ab concentrations tended to have poorer cardiovascular outcomes in the subsequent demonstrated a higher incidence of cardiovascular deaths in the ensuing 12 months (n = 16, p = 0.067), although this failed to achieve significance. Likewise, no significant differences in the incidence of either stroke or myocardial re-infarction were observed within the entire cohort (p = 0.06), with sub-group analyses in patients \< 60 years (n = 388) revealing that low anti-ß~1~AR Ab concentrations were associated with the incidence of re-infarction within 12 months (p = 0.010, Fig. [1](#Fig1){ref-type="fig"}). Considering all cardiovascular events collectively across these patients, patients with lower anti-β~1~AR Ab concentrations were associated with higher rates of adverse outcomes (p = 0.017, Fig. [2A](#Fig2){ref-type="fig"}).Figure 1Kaplan-Meier curves for spontaneous MI over and under median ß1-AdrR-ab concentrations. Kaplan-Meier curves are stratified according to age groups. Number of events: all patients 48 (**A**), patients ≤60 years 16 (**B**) and patients \>60 years 32 (**C**). ß1-AR ab below median was associated with a higher incidence of re-infarction in younger patients, particularly within the first 8 weeks. No differences were observed in patients \>60 years (**C**) or all patients (**A**). P-values calculated using Cox-proportional hazards Score-Test.Figure 2Kaplan-Meier curve summarizing all-cause cardiovascular mortality in the first 12 months after the index acute coronary syndrome with respect to ß1-AR ab level at original presentation for patients ≤60 years (**A**) and all patients (**B**). Once again, lower ß1-AR ab levels were associated with a higher incidence of fatal events in patients aged ≤60 years. In older patients, no differences were observed (p = 0.961, data suppl.). Number of events: 22 (**A**) und 69 (**B**). P-values calculated using Cox-proportional hazards Score-Test.

In relation to spontaneous MI, patients with anti-ß~1~AR Ab concentrations ≤ median values appeared to incur a significantly higher number of events (n = 16; p = 0.010, Fig. [1](#Fig1){ref-type="fig"}) among younger patients ≤60 years. In older patients, spontaneous MI rates appeared largely independent of antibody concentration (n = 32; p = 0.186), Fig. [1C](#Fig1){ref-type="fig"}.

### Anti-ß~1~AR Ab and conventional clinical risk factors {#Sec9}

Between the stratified anti-ß~1~AR Ab concentration groups, no differences in the incidence or distribution of conventional risk factors across all patients were observed. Weak trends suggesting an association between lower anti-ß~1~AR Ab concentrations and increased incidence of diabetes mellitus (23.8% vs. 18.0%; p = 0.055) and dyslipidemia (45.5% vs. 39.1%; p = 0.073) were observed, levels (p = 0.055 and p = 0.073) in both groups were evident but neither achieved outright significance. Statin use was associated with higher anti-ß~1~AR Ab levels (p = 0.009).

Among patients ≤60 years, those exhibiting lower anti-ß~1~AR Ab concentrations had higher rates of diabetes mellitus (20.2 *vs*. 11.6%; p = 0.026) and were less likely to be receiving statins at study inclusion (83.8 vs. 91.6%; p = 0.021). Otherwise no differences in clinical risk factors in younger patients correlated with anti-ß~1~AR Ab concentrations (Table [SD7](#MOESM1){ref-type="media"}).

### Anti-ß~1~AR Ab and ACS biomarkers {#Sec10}

Within the stratified anti-ß~1~AR Ab groups, the only serum biomarker demonstrating an inter-group difference was C-reactive protein, which was higher among patients with higher anti-ß~1~AR Ab concentrations (2.7 \[1.2--6.2\]mg/L vs. 3.5 \[1.4--8.4\]mg/L; p = 0.018). Further analysis, quantitively comparing the actual measured anti-ß~1~AR Ab concentrations with the respective serum biomarkers using the Spearman Rank Correlation test however confirmed that anti-ß~1~AR Ab did not correlate with any of the available biomarkers, apolipoprotein A1 and B, Cystatin, Troponin I and T, NT-proBNP, GDF-15, GFR and IL-6 (all coefficients R~s~ \< ± 0.10; Supplemental Data Sheet, Fig. [SD1](#MOESM1){ref-type="media"} and Table [SD8](#MOESM1){ref-type="media"}).

Discussion {#Sec11}
==========

Anti-ß~1~AR Ab levels in ACS {#Sec12}
----------------------------

Across the entire cohort, empirical cumulative distribution functions of anti-ß~1~AR Ab concentrations revealed significantly higher values in STEMI than NSTEMI (p \< 0.001), which retained significance following stratification for age \> or ≤60 years (both p \< 0.001; see Supplementary Data Sheet, Fig. [SD2](#MOESM1){ref-type="media"}).

Overall, anti-ß~1~AR Ab concentrations across all 799 ACS patients failed to show any meaningful association~~s~~ to either survival or re-infarction in the first year. Subgroup analyses using both unadjusted and adjusted Cox Regression Models demonstrated that younger patients with anti-ß~1~AR Ab concentrations ≤ median were less likely to remain free of either re-infarction (HR 0.14 \[0.03--0.63\]; p = 0.01) or any cardiovascular event~~s~~ (HR 0.30 \[0.11--0.80\]; p = 0.017), impacting inherently on event-free survival (Fig. [1](#Fig1){ref-type="fig"}). These findings corroborate to an extent earlier data, which suggested a worse outcome for ACS patients with low anti-ß~1~AR Ab levels^[@CR14]^.

Furthermore, the current study associates lower Ab concentration with increased rates of early re-infarction, similar to trends seen in particular ACS sub-groups in our previous paper. To our knowledge, no biomarkers are routinely used in risk stratification for re-infarction, whilst only a few biomarkers such as GDF-15 or NT-proBNP are of proven prognostic relevance after ACS^[@CR3],[@CR21]^, particularly in combination^[@CR22]^. Future studies are needed, to explore if anti-ß~1~AR Ab could provide additional insight in such cases.

In contrast to previous data on anti-ß~1~AR Ab in ACS, which suggested that lower concentrations were found in STEMI compared to NSTEMI, both of which were markedly reduced compared to healthy controls^[@CR14]^, the current study revealed higher concentrations in STEMI patients compared to NSTEMI. This may reflect, that STEMI is not automatically associated with greater injury or poorer worse outcome, as multiple additional confounders may have reasonably influenced mortality and prognosis^[@CR23]--[@CR25]^. STEMI patients are younger (FAST MI study 63.5 ± 13.8 (STEMI) vs. 68.1 ± 13.5 (NSTEMI)) and have a more transmural muscle damage, whilst NSTEMI patients are older, have more comorbidities and commonly a greater severity of coronary vascular disease. Therefore, NSTEMI patients have a lower early mortality but higher risk for long-term mortality compared to STEMI patients^[@CR26]^.

Conceivably, our results regarding anti-ß~1~AR Ab concentrations in different ACS phenotypes may merely reflect demographic differences within the cohort~~s~~ rather than any direct effect of anti-ß~1~AR Ab. It should be reiterated that the inclusion criteria for the PLATO trial excluded patients \<60 years *without* known vascular comorbidities. Our original cohort was by contrast composed of particularly young ACS patients (NSTEMI median age 57 (48--61) years and STEMI 52(41--58) years) independent of comorbidities or known cardiac risk factors.

The results go along with the finding that anti-ß~1~AR Ab levels are independent of troponin or CK-values, suggesting no correlation to myocardial muscle damage.

Due to the lack of knowledge about the exact function of anti-ß~1~AR Ab, there are several possible explanations for these results. One could be a worse response to betablocker therapy. Nagatomo *et al*. have shown that patients with heart failure and evidence of anti-ß1AR Ab responded significantly better to betablocker therapy than patients with no increased anti-ß~1~AR Ab concentrations. Patients positive for anti-ß~1~AR Ab had for example a greater improvement in ejection fraction, greater changes of the left ventricular end-diastolic dimension and tended to have a better reduction of pro-BNP^[@CR27]^.

A possible effect of betablocker therapy in our cohort is difficult to analyze as betablocker were taken in both groups, STEMI and NSTEMI, up to 80% of the patients before the ACS and nearly 100% after ACS. Even the following thesis is highly speculative, it could well be, that in earlier analyses patients with low anti-ß~1~AR Ab levels just did worse because they did not respond to ß-blocker treatment.

Another explanation for our results could be a stronger agonistic effect of anti-ß~1~AR Ab due to higher expression of ß~1~AR during and after an ACS^[@CR28]^. This up-regulation of ß~1~AR may lead to a high binding of anti-ß~1~AR Ab and therefore falling levels in serum in ACS patients in general^[@CR14]^. Suggesting a protective or blocking role of anti-ß~1~AR Ab on the receptors, the natural ligand adrenalin could stimulate the receptor stronger leading to vasoconstriction and worse outcome.

Statin use was associated with higher ab levels. Based on the role of statins in the prevention of infarction, high ab levels could be more beneficial.

Risk factors and routinely used ACS biomarker {#Sec13}
---------------------------------------------

Based upon comparisons to conventional cardiac risk factors, no significant correlations to anti-ß~1~AR concentrations were observed. This may further supports the hypothesis of an additional autoimmune component to cardiovascular disease. Further research looking at the immunological aspects in RF-naïve ACS patients is needed. Whilst previous work has shown contradictory results regarding dyslipidemia^[@CR14]^, we can show only trends towards a correlation with lower levels of anti-ß~1~AR Ab (p = 0.073).

It has to be noted, that the specific function of anti-ß~1~AR Ab may rely greatly on its binding antigen to the receptor, which could partially explain the contradicting results regarding the effect of anti-ß~1~AR Ab^[@CR29]^.

Although levels for CRP were significantly higher in patients with high anti-ß~1~AR Ab 2.7 (1.2--6.2) mg/l versus 3.5 (1.4--8.4) mg/l (p = 0.018), values for IL-6 were not different, suggesting IL-6-independent associations for this observation.

Anti-ß~1~AR Ab levels in congestive heart disease {#Sec14}
-------------------------------------------------

Our results compliment the association of anti-ß~1~AR Ab with chronic heart failure, showing a significant increase of anti-ß~1~AR Ab in congestive heart failure (p = 0.014). Several anti-ß~1~AR Ab associated diseases are known to lead to chronic heart failure, such as dilated cardiomyopathy^[@CR30]^, Chagas disease^[@CR31]^ and atrial fibrillation^[@CR32],[@CR33]^.

Limitations {#Sec15}
-----------

The aim of the current analysis was to validate the findings of our previous single center study in a large, well-characterized cohort. Despite the larger number~~s~~ of patients involved, this approach also introduced a number of further limitations to the current analysis.

The existing results suggested that the relevance of anti-ß~1~AR Ab in ACS was primarily in patients below the age of 60 years. Whilst the PLATO cohort included many such patients, there is an inherent inclusion bias against younger patients with no comorbidity. It is also unclear, what if any influence a previous cardiac event prior to the index event would have on antibody concentration. In this respect, limiting analysis to first presentation only may have been prudent.

Although the number of patients analyzed was high (n = 799), numbers of re-infarction, cardiovascular death and all-cause death were comparably low, hampering statistical analysis of subgroups.

Similarly, the cohort lacks a suitably matched healthy control group, we were not able to assess if the significance of anti-ß~1~AR Ab concentrations actually relates to the presence of an ACS or not.

The lack of understanding about the exact function of anti-ß~1~AR Ab is another main limitation. Therefore, the interpretation of our results remains speculative. Functional tests and longitudinal measurements are needed to further explore the functional influence and effect of anti-ß~1~AR Ab.

Conclusion {#Sec16}
==========

Lowered titers of anti-ß~1~AR Ab in serum of ACS patients may be associated with higher risk for re-infarction or worse prognosis. These results have shown the greatest significance in patients below the age of 60 years. In this subgroup low anti-ß~1~AR Ab concentrations were associated with re-infarction (p = 0.01) and all cardiovascular events (p = 0.017) within 12 months after the index event. An association between low anti-ß~1~AR Ab and ACS compared to healthy controls and patients with atherosclerosis as well as a possible negative prognostic factor for survival and re-infarction has been shown recently^[@CR14]^.

Larger cohorts are needed to finally confirm our findings. Furthermore functional analyses are necessary to understand the effect of anti-ß~1~AR Ab during and after ACS.

Supplementary information
=========================

 {#Sec17}

Supplementary Data

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Gabriela Riemekasten and Torsten Witte jointly supervised this work.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1038/s41598-019-51125-9.

The authors like to thank the laboratory staff of CellTrend for performing the ELISA tests. Diana Ernst is supported by a Government Grant Ellen-Schmidt 2018 of Hannover Medical School, Germany. Gerrit Ahrenstorf and Alexandra Jablonka were funded by the Young Academy Clinician/Scientist program of Hannover Medical School, Germany. The project was supported by KFO 250 of the German research foundation. Laboratory staff of CellTrend performed ELISA testing.

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. Contribution to the manuscript. D.E. conception and design of the study, acquisition and interpretation of data, drafting the article, and final approval of the version to be submitted. G.A., A.J., G.S. and R.E.S. interpretation of data, revising critically for important intellectual content and final approval of the version to be submitted. H.H. acquisition of data, revising critically for important intellectual content and final approval of the version to be submitted. J.W. analyses, interpretation of data, revising critically for important intellectual content and final approval of the version to be submitted. L.W., G.R. and T.W. conception and design of the study, interpretation of data, revising critically for important intellectual content and final approval of the version to be submitted.

H.H. is the owner of CellTrend. CellTrend had no influence in data analysis. All other authors declare no conflict of interest.
